A Phase III Confirmatory Study of K-877 Extended Release Tablet

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.

Also called NCT04714151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 356 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04714151
Other papers using this trial's data
  • Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial Journal of atherosclerosis and thrombosis, 2024-11-01 DOI, PubMed 38616112, PMC11537784 In the PMC Open Access subset under CC BY-NC-SA.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04714151. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2021-09-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Confirmatory Study of K-877 Extended Release Tablet
Condition
Dyslipidemias
Intervention (Drug)
K-877 ER 0.2 mg/day (once daily)
Intervention (Drug)
K-877 ER 0.4 mg/day (once daily)
Intervention (Drug)
K-877 IR 0.2 mg/day (twice daily)
Lead sponsor
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04714151
Content hash
bcacf4b14f175935e904bc068c2c4010ebe49341ebf6c789ec14d7ea701badcb